Prescription drugs in oncology reach peak sales five to seven years post-launch
The most lucrative geographies for new oncology drugs seem to be those in which peak sales have a shorter timeframe.
Oncology
AbCellera and Everest enter deal to discover antibody therapies
Everest will make research, milestone and royalty payments to AbCellera for the products developed through...
Boehringer acquires Abexxa Biologics to develop new cancer treatments
Through the acquisition, Boehringer will now have access to Abexxa’s expertise in targeting cancer-specific proteins.
Adaptimmune Q&A: an alternative approach to T-cell cancer therapies
Adaptimmune’s chief business officer discusses the company’s T-cell research, and its hopes for a new...
Study identifies possible link between antibiotic use and breast cancer growth
Researchers have investigated how disrupting a healthy balance of bacteria in the gut impacts breast...
UK MHRA approves Amgen’s sotorasib for non-small cell lung cancer treatment
With the approval, the drug will be offered under NHS to eligible lung cancer patients in England soon.
Adaptimmune and Genentech partner for allogeneic cell therapies development
Adaptimmune will receive an upfront payment of $150m from Genentech and further payments of $150m over five years.
Global HER2+ breast cancer ADC market to reach $3.3bn by 2030
GlobalData expects HER2+ breast cancer to remain at the heart of innovation for the antibody-drug conjugate (ADC) modality.
Multiple myeloma: first bispecific mAb to secure r/r approval will have biggest market bite
Market latecomers will likely struggle to demonstrate value-added edge so early strategic decisions are critical.
Dr Reddy’s agrees to transfer rights of anti-cancer assets to Citius
Under the deal, Dr Reddy’s is eligible to receive $40m as an upfront payment from Citius on the closing of the deal.
EC grants orphan drug status to Novartis’ sabatolimab for MDS treatment
The FDA granted fast track status to the drug in May for use along with hypomethylating agents.
